Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1982;60:583-586
© 1982 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LAUFER, L. R.
Right arrow Articles by ]UDD, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LAUFER, L. R.
Right arrow Articles by ]UDD, H. L.

Effect of Clonidine on Hot Flashes in Postmenopausal Women

LARRY R. LAUFER, MD, YOHANAN ERLIK, MD, DAVID R. MELDRUM, MD and HOWARD L. ]UDD, MD

From the Department of Obstetrics and Gynecology, UCLA School of Medicine, Los Angeles, California

Abstract

The effectiveness of clonidine in suppressing the occurrence of postmenopausal hot flashes was examined using a doseresponse study design and objective recordings of hot flashes. Patients with frequent flashes were studied before and after oral administration of placebo and 0.1, 0.2, and 0.4 mg of clonidine daily for 2 weeks at each dose level. Finger temperature and skin resistance were recorded as indices of hot flash episodes. Four of 10 subjects beginning the study withdrew because of drug-related side effects. Clonidine was found to reduce significantly the frequency of hot flashes as compared with baseline (P<.005) and with effects of the placebo (P<.05). At the maximum dosage the mean rate of hot flash occurrence decreased 46%. It was concluded that clonidine does reduce the frequency of postmenopausal flashes.




This article has been cited by other articles:


Home page
 Ann OncolHome page
S Loibl, K Schwedler, G von Minckwitz, R Strohmeier, K. Mehta, and M Kaufmann
Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study
Ann. Onc., April 1, 2007; 18(4): 689 - 693.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. H. Boekhout, J. H. Beijnen, and J. H.M. Schellens
Symptoms and treatment in cancer therapy-induced early menopause.
Oncologist, June 1, 2006; 11(6): 641 - 654.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
C. E. Piersen
Phytoestrogens in Botanical Dietary Supplements: Implications for Cancer
Integr Cancer Ther, June 1, 2003; 2(2): 120 - 138.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
K. J. Pandya, R. F. Raubertas, P. J. Flynn, H. E. Hynes, R. J. Rosenbluth, J. J. Kirshner, H. I. Pierce, V. Dragalin, and G. R. Morrow
Oral Clonidine in Postmenopausal Patients with Breast Cancer Experiencing Tamoxifen-Induced Hot Flashes: A University of Rochester Cancer Center Community Clinical Oncology Program Study
Ann Intern Med, May 16, 2000; 132(10): 788 - 793.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. V. Pinkerton and R. Santen
Alternatives to the Use of Estrogen in Postmenopausal Women
Endocr. Rev., June 1, 1999; 20(3): 308 - 320.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1982 by the American College of Obstetricians and Gynecologists.